135 related articles for article (PubMed ID: 28092869)
1. Chronic myelogenous leukemia evolving after treatment of multiple myeloma.
Wolleschak D; Heidel FH
Blood; 2016 Jul; 128(1):146. PubMed ID: 28092869
[No Abstract] [Full Text] [Related]
2. A rare case of chronic myelogenous leukemia and plasma cell myeloma in the same patient.
Ahn S; Park JS; Han JH; Cho SR
Ann Lab Med; 2015 May; 35(3):370-2. PubMed ID: 25932449
[No Abstract] [Full Text] [Related]
3. Uncommon case of chronic myeloid leukemia with multiple myeloma.
Ide M; Kuwahara N; Matsuishi E; Kimura S; Gondo H
Int J Hematol; 2010 May; 91(4):699-704. PubMed ID: 20352382
[TBL] [Abstract][Full Text] [Related]
4. Aggregates of Pseudogaucher Cells in a Pediatric Patient With Chronic Myeloid Leukemia.
Roldán Galiacho V; Moreno Gamiz M; Echebarrria-Barona A
J Pediatr Hematol Oncol; 2021 Aug; 43(6):224-225. PubMed ID: 34054044
[No Abstract] [Full Text] [Related]
5. Case Report: IgG multiple myeloma and chronic myeloid leukemia in a single patient.
Swaminathan N; Gupta S; Dourado C
F1000Res; 2020; 9():488. PubMed ID: 33042520
[TBL] [Abstract][Full Text] [Related]
6. Complete cytogenietic remission with imatinib mesylate treatment in chronic myelogenous leukemia (CML) developed after renal transplantation.
Koca E; Cetiner D; Goker H; Aksu S; Ozcebe OI; Haznedaroglu IC; Turgan C
Clin Nephrol; 2005 Oct; 64(4):324-6. PubMed ID: 16240908
[No Abstract] [Full Text] [Related]
7. Promyelocytic Blastic Crisis in Chronic Myeloid Leukemia During Imatinib Treatment.
Angriman F; Gutierrez Acevedo MN; Rossi MS; Gimenez Conca AD; Otero V; Arbelbide JA; Michelángelo H
Turk J Haematol; 2015 Jun; 32(2):193-4. PubMed ID: 26316496
[No Abstract] [Full Text] [Related]
8. Chronic myeloid leukemia arising from acute myeloid leukemia: response to imatinib mesylate with favorable outcome.
Xu XH; Huang LS; Yang J; Yu T; Tong JF; Yuan XG; Zhao XY
Leuk Lymphoma; 2013 Jan; 54(1):195-7. PubMed ID: 22574970
[No Abstract] [Full Text] [Related]
9. Rapid conversion of chronic myeloid leukemia to chronic myelomonocytic leukemia in a patient on imatinib therapy.
Khorashad JS; Tantravahi SK; Yan D; Mason CC; Qiao Y; Eiring AM; Gligorich K; Hein T; Pomicter AD; Reid AG; Kelley TW; Marth GT; O'Hare T; Deininger MW
Leukemia; 2016 Nov; 30(11):2275-2279. PubMed ID: 27480386
[No Abstract] [Full Text] [Related]
10. The beauty and the beast: lymphoma-like morphology of myeloid blast phase in CML.
Asemissen AM; Dierlamm J
Blood; 2017 Sep; 130(10):1274. PubMed ID: 28882836
[No Abstract] [Full Text] [Related]
11. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
[TBL] [Abstract][Full Text] [Related]
12. Persistence with generic imatinib for chronic myeloid leukemia: a matched cohort study.
Klil-Drori AJ; Yin H; Azoulay L; Harnois M; Gratton MO; Busque L; Assouline SE;
Haematologica; 2019 Jul; 104(7):e293-e295. PubMed ID: 30630987
[No Abstract] [Full Text] [Related]
13. Incidence of Myelofibrosis in Chronic Myeloid Leukemia, Multiple Myeloma, and Chronic Lymphoid Leukemia during Various Phases of Diseases.
Dolgikh TY; Domnikova NP; Tornuev YV; Vinogradova EV; Krinitsyna YM
Bull Exp Biol Med; 2017 Feb; 162(4):483-487. PubMed ID: 28239786
[TBL] [Abstract][Full Text] [Related]
14. Bone marrow with gelatinous transformation associated with residual disease in imatinib mesylate-treated chronic myelogenous leukaemia (CML).
Thakral B; Higa B; Venkataraman G; Velankar MM
Pathology; 2012 Jan; 44(1):59. PubMed ID: 22157697
[No Abstract] [Full Text] [Related]
15. Development of multiple myeloma in a patient with chronic myeloid leukemia after treatment with imatinib mesylate.
Garipidou V; Vakalopoulou S; Tziomalos K
Oncologist; 2005; 10(6):457-8. PubMed ID: 15967839
[No Abstract] [Full Text] [Related]
16. Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia.
Tanrikulu Simsek E; Eskazan AE; Cengiz M; Ar MC; Ekizoglu S; Salihoglu A; Gulturk E; Elverdi T; Ongoren Aydin S; Senem Demiroz A; Buyru AN; Baslar Z; Ozbek U; Ferhanoglu B; Aydin Y; Tuzuner N; Soysal T
J Clin Pathol; 2016 Sep; 69(9):810-6. PubMed ID: 26811428
[TBL] [Abstract][Full Text] [Related]
17. Reduced circulating B-lymphocytes and altered B-cell compartments in patients suffering from chronic myeloid leukaemia undergoing therapy with Imatinib.
Carulli G; Baratè C; Marini A; Ottaviano V; Cervetti G; Fontanelli G; Guerrini F; Arici R; Guerri V; Di Paolo A; Polillo M; Ferreri MI; Galimberti S; Petrini M
Hematol Oncol; 2015 Dec; 33(4):250-2. PubMed ID: 25256816
[No Abstract] [Full Text] [Related]
18. Imatinib--A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015.
Gambacorti-Passerini C; Piazza R
JAMA Oncol; 2015 May; 1(2):143-4. PubMed ID: 26181011
[No Abstract] [Full Text] [Related]
19. Chronic myeloid leukemia with a rare fusion transcript, e19a2 BCR-ABL1: A report of three cases from India.
Sazawal S; Chikkara S; Singh K; Chaubey R; Chandra D; Mishra P; Mahapatra M; Seth T; Saxena R
Ann Diagn Pathol; 2017 Apr; 27():24-27. PubMed ID: 28325357
[TBL] [Abstract][Full Text] [Related]
20. Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status.
Frater JL; Tallman MS; Variakojis D; Druker BJ; Resta D; Riley MB; Hrisinko MA; Peterson LC
Am J Clin Pathol; 2003 Jun; 119(6):833-41. PubMed ID: 12817431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
